Targeting ApoB as a therapeutic approach forthe treatment of dyslipidemia: The potential role of mipomersen

Clinical Lipidology

Volumn 5, Issue 4, 2010, Pages 457-464

  Thomas, Tiffany ^a   Ginsberg, Henry ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

antisense oligonucleotide; ApoB; dyslipidemia; LDL C; mipomersen

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B; BMS 201038; EZETIMIBE; HYPOCHOLESTEROLEMIC AGENT; ISIS 147764; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIPOMERSEN; PLACEBO; PROTEIN INHIBITOR; SIMVASTATIN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FATTY LIVER; FLU LIKE SYNDROME; HEADACHE; HEMATOMA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INJECTION SITE DISCOLORATION; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; LIPID TRANSPORT; MUSCLE FATIGUE; NAUSEA; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT RESPONSE;

ANIMALIA;

EID: 77955601936     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/clp.10.47     Document Type: Review

References (49)

1. Baigent C, Keech A, Kearney PM et al.: Efficacy and safety of cholesterol-lowering treatment: prospective meta analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493), 1267-1278 (2005).
2. Andrews TC, Ballantyne CM, Hsia JA et al.: Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am. J. Med. 111(3), 185-191 (2001).
3. Law M, Rudnicka AR: Statin safety: a systematic review. Am. J. Cardiol. 97(8A), 52C-60C (2006).
4. Alberts AW: Lovastatin and simvastatin-inhibitors of HMG CoA reductase and cholesterol biosynthesis. Cardiology 77(Suppl. 4), 14-21 (1990).
5. Rader DJ, Cohen J, Hobbs HH: Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J. Clin. Invest. 111(12), 1795-1803 (2003).
6. Smiley III WH, Khan BV, Sperling LS: Management of the statin-intolerant patient. Curr. Treat. Options Cardiovasc. Med. 11(4), 263-271 (2009).
7. Hou R, Goldberg AC: Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety. Endocrinol. Metab. Clin. North Am. 38(1), 79-97 (2009).
8. Rader DJ, Brewer HB Jr: Abetalipoproteinemia. New insights into lipoprotein assembly and vitamin E metabolism from a rare genetic disease. JAMA 270(7), 865-869 (1993).
9. Linton MF, Farese RV Jr, Young SG: Familial hypobetalipoproteinemia. J. Lipid Res. 34(4), 521-541 (1993).
10. Schonfeld G, Patterson BW, Yablonskiy DA et al.: Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis. J. Lipid Res. 44(3), 470-478 (2003).
11. Young SG: Recent progress in understanding apolipoprotein B. Circulation 82(5), 1574-1594 (1990).
12. Davidson NO, Shelness GS: Apolipoprotein B: mRNA editing, lipoprotein assembly, and presecretory degradation. Annu. Rev. Nutr. 20, 169-193 (2000).
13. Farese RV Jr, Ruland SL, Flynn LM et al.: Knockout of the mouse apolipoprotein B gene results in embryonic lethality in homozygotes and protection against diet-induced hypercholesterolemia in heterozygotes. Proc. Natl Acad. Sci. USA 92(5), 1774-1778 (1995).
14. Tanoli T, Yue P, Yablonskiy D et al.: Fatty liver in familial hypobetalipoproteinemia: roles of the ApoB defects, intra-abdominal adipose tissue, and insulin sensitivity. J. Lipid Res. 45(5), 941-947 (2004).
15. Sankatsing RR, Fouchier SW, de Haan S et al.: Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia. Arterioscler. Thromb. Vasc. Biol. 25(9), 1979-1984 (2005).
16. Mitchell DM, Zhou M, Pariyarath R et al.: Apoprotein B100 has a prolonged interaction with the translocon during which its lipidation and translocation change from dependence on the microsomal triglyceride transfer protein to independence. Proc. Natl Acad. Sci. USA 95(25), 14733-14738 (1998).
17. Samaha FF, McKenney J, Bloedon LT et al.: Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat. Clin. Pract. Cardiovasc. Med. 5(8), 497-505 (2008).
18. Cuchel M, Bloedon LT, Szapary PO et al.: Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N. Engl. J. Med. 356(2), 148-156 (2007).
19. Chandler CE, Wilder DE, Pettini JL et al.: CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J. Lipid Res. 44(10), 1887-1901 (2003).
20. Kurreck J: Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem. 270(8), 1628-1644 (2003).
21. Crooke ST: Progress in antisense technology. Annu. Rev. Med. 55, 61-95 (2004).
22. Yu RZ, Kim TW, Hong A et al.: Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab. Dispos. 35(3), 460-468 (2007).
23. Crooke RM, Graham MJ, Lemonidis KM et al.: An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J. Lipid Res. 46(5), 872-884 (2005).
24. Preiss D, Sattar N: Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin. Sci. (Lond.) 115(5), 141-150 (2008).
25. Fabbrini E, Sullivan S, Klein S: Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51(2), 679-689 (2010).
26. Mullick AE, Graham MJ, Crooke RM: Antisense Inhibition of apolipoprotein B ameliorated diet-induced hypercholesterolemia and reduced atherosclerosis in LDL receptor-deficient mice. Presented at: Arteriosclerosis, Thrombosis and Vascular Biology Annual Conference 2008. Atlanta, GA, USA, 16-18 April 2008.
27. Berglund L, Ramakrishnan R: Lipoprotein(a): an elusive cardiovascular risk factor. Arterioscler. Thromb. Vasc. Biol. 24(12), 2219-2226 (2004).
28. Merki E, Graham MJ, Mullick AE et al.: Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation 118(7), 743-753 (2008).
29. Yu RZ, Lemonidis KM, Graham MJ et al.: Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem. Pharmacol. 77(5), 910-919 (2009).
30. Akdim F, Stroes ES, Sijbrands EJ et al.: Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J. Am. Coll. Cardiol. 55(15), 1611-1618 (2010).
31. Yu RZ, Geary RS, Flaim JD et al.: Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2′-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin. Pharmacokinet. 48(1), 39-50 (2009).
32. Kastelein JJ, Wedel MK, Baker BF et al.: Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 114(16), 1729-1735 (2006).
33. Raal FJ, Santos RD, Blom DJ et al.: Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 375(9719), 998-1006 (2010).
34. Visser ME, Akdim F, Tribble DL et al.: Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J. Lipid Res. 51, 1057-1062 (2010).
35. Hardee E, Lindhold M, Hansen H et al.: Pharmacology, target reduction, and drug accumulation after oral feeding of an LNA antisense oligonucleotide directed against Apo-B 100. Presented at: Arteriosclerosis, Thrombosis and Vascular Biology Annual Conference 2010. San Francisco, CA, USA, 8-10 April 2010. 23
36. Crooke RM, Graham MJ, Lemonidis KM et al.: An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J. Lipid Res. 46(5), 872-884 (2005).
37. Preiss D, Sattar N: Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin. Sci. (Lond.) 115(5), 141-150 (2008).
38. Fabbrini E, Sullivan S, Klein S: Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51(2), 679-689 (2010).
39. Mullick AE, Graham MJ, Crooke RM: Antisense Inhibition of apolipoprotein B ameliorated diet-induced hypercholesterolemia and reduced atherosclerosis in LDL receptor-deficient mice. Presented at: Arteriosclerosis, Thrombosis and Vascular Biology Annual Conference 2008. Atlanta, GA, USA, 16-18 April 2008.
40. Berglund L, Ramakrishnan R: Lipoprotein(a): an elusive cardiovascular risk factor. Arterioscler. Thromb. Vasc. Biol. 24(12), 2219-2226 (2004).
41. Merki E, Graham MJ, Mullick AE et al.: Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation 118(7), 743-753 (2008).
42. Yu RZ, Lemonidis KM, Graham MJ et al.: Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem. Pharmacol. 77(5), 910-919 (2009).
43. Akdim F, Stroes ES, Sijbrands EJ et al.: Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J. Am. Coll. Cardiol. 55(15), 1611-1618 (2010).
44. Yu RZ, Geary RS, Flaim JD et al.: Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2′-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin. Pharmacokinet. 48(1), 39-50 (2009).
45. Kastelein JJ, Wedel MK, Baker BF et al.: Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 114(16), 1729-1735 (2006).
46. Raal FJ, Santos RD, Blom DJ et al.: Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 375(9719), 998-1006 (2010).
47. Visser ME, Akdim F, Tribble DL et al.: Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J. Lipid Res. 51, 1057-1062 (2010).
48. Hardee E, Lindhold M, Hansen H et al.: Pharmacology, target reduction, and drug accumulation after oral feeding of an LNA antisense oligonucleotide directed against Apo-B 100. Presented at: Arteriosclerosis, Thrombosis and Vascular Biology Annual Conference 2010. San Francisco, CA, USA, 8-10 April 2010.
49. Clinical trials website containing details of Phase II/III studies of mipomersen www.clinicaltrials.gov/ct2/ results?term=301012101 Clinical trials website containing details of Phase II/III studies of mipomersen www.clinicaltrials.gov/ct2/ results?term=301012